Cart
sales@molnova.com
BMS-P5 free base
CAS No. 1550371-22-6
BMS-P5 free base( —— )
Catalog No. M22888 CAS No. 1550371-22-6
BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 74 | In Stock |
|
| 10MG | 131 | In Stock |
|
| 25MG | 267 | In Stock |
|
| 50MG | 480 | In Stock |
|
| 100MG | 683 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-P5 free base
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.
-
DescriptionBMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression Targeting PAD4 may be beneficial for treatment of multiple myeloma.Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression.
-
In VitroCell Viability Assay.Cell Line:Neutrophils.Concentration:10 μM and 100 μM.Incubation Time:30 min followed by addition of DP42 or 5TGM1 CM.Result:Prevented MM-induced NET formation.
-
In VivoAnimal Model:Syngeneic mouse model of MM.Dosage:50 mg/kg.Administration:Oral gavage, twice a day beginning on day 3 after tumor cell injection.Result:Significantly delayed development of symptoms and significantly prolonged survival of MM-bearing mice.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptorpeptidylarginine deiminase 4 (PAD4)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1550371-22-6
-
Formula Weight472.58
-
Molecular FormulaC27H32N6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (529.01 mM)
-
SMILESO=C(N1[C@@H](C)CC[C@@H](N)C1)C2=CC(OC)=C3C(N=C(C4=CC5=CC=CN=C5N4CC6CC6)N3C)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
ELA-32 (human)
Potent, high affinity apelin receptor agonist (IC50 = 0.27 nM; Kd = 0.51 nM). Exhibits no binding GPR15 and GPR25. Activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. Also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. Stimulates angiogenesis in HUVEC cells. Relaxes mouse aortic vessels. Functions as an anorexigenic hormone through activation of the AVP and CRH neurons in the PVN.
-
Halofenozide
Halofenozide is an ecdysteroid agonist and used as a pesticide.
-
Ethyl docosa-4,7,10,...
Ethyl cis-4,7,10,13,16,19-Docosahexaenoate, the ethyl ester of Docosahexaenoate (DHA), is selectively enriched in the ethyl ester fraction through alcoholysis using fatty acid ethyl esters from tuna oil and lauryl alcohol.
